LIVZON PHARMA (01513) announced that its subsidiary, Zhuhai Livzon Monoclonal Antibody Biotechnology Co., Ltd., has received a Drug Clinical Trial Approval Notice (Notice No.: 2026LP03262) from the National Medical Products Administration.
The approval permits the clinical trial of the recombinant humanized anti-FXI bispecific antibody injection filed by Livzon Monoclonal Antibody for the indication of "prevention of venous thromboembolism after total knee arthroplasty."